Pomerantz Law Firm Issues Class Action Reminder for GSK Investors Ahead of April Deadline
On March 3, 2025, Pomerantz LLP announced the initiation of a class action lawsuit against GSK plc, also known as GlaxoSmithKline, a pharmaceutical giant based in the UK, over allegations of securities fraud. Investors who believe they suffered losses due to their investments in GSK are encouraged to take action before the upcoming deadline of April 7, 2025, for appointing a Lead Plaintiff in the case. This situation comes in the wake of significant challenges faced by GSK concerning its product Zantac, a widely used medication.
In late 2019, GSK decided to halt the distribution of Zantac, known generically as ranitidine, as studies revealed that the drug could form a cancer-causing agent, N-nitrosodimethylamine (NDMA) when interacting with nitrites. This alarming discovery led to a voluntary recall, raising serious concerns about the safety of the medication and the company’s practices.
Financial analysts from Deutsche Bank have pointed out that GSK and other Zantac distributors might face substantial liabilities, estimating potential damages ranging from $5 billion to $10 billion. Following the release of this information in 2022, GSK’s American depositary receipt (ADR) prices fell significantly, highlighting the immediate impact of these allegations on investor confidence. The ADR price plummeted by 10.74% within just two trading sessions after the Deutsche Bank report, closing at $35.73.
Subsequently, on August 15, 2022, GSK publicly acknowledged its exposure to liabilities relating to Zantac, further deteriorating its stock price by 3% to close at $34.95. This disclosure has left many investors questioning the company's responsibility regarding its products and the potentially extensive repercussions of these legal challenges.
As Pomerantz LLP proceeds with the class action lawsuit, investors are reminded to gather necessary details when reaching out regarding participation in the lawsuit. Danielle Peyton, a representative from Pomerantz LLP, urges those interested to contact her directly, highlighting the importance of including personal details such as a mailing address and phone number for effective communication.
Founded by the late Abraham L. Pomerantz, regarded as a pioneer in the field of securities class actions, Pomerantz LLP boasts a legacy of over 85 years in advocating for investors affected by corporate misconduct. The firm has garnered a reputation for recovering lucrative damages for class members, emphasizing their commitment to justice in the realm of securities fraud.
In light of these developments, affected investors are encouraged to act swiftly to ensure their rights are protected and to obtain the requisite documentation concerning the case. The implications of the class action lawsuit could have significant impacts on GSK as well as its stakeholders, making it imperative for investors to stay informed about the situation and upcoming legal proceedings.
Potential participants can visit the Pomerantz LLP website, www.pomerantzlaw.com, for more information and to access the relevant legal documents. As the situation unfolds, stakeholders will be closely watching how the legal landscape impacts GSK and the pharmaceutical industry at large.
In late 2019, GSK decided to halt the distribution of Zantac, known generically as ranitidine, as studies revealed that the drug could form a cancer-causing agent, N-nitrosodimethylamine (NDMA) when interacting with nitrites. This alarming discovery led to a voluntary recall, raising serious concerns about the safety of the medication and the company’s practices.
Financial analysts from Deutsche Bank have pointed out that GSK and other Zantac distributors might face substantial liabilities, estimating potential damages ranging from $5 billion to $10 billion. Following the release of this information in 2022, GSK’s American depositary receipt (ADR) prices fell significantly, highlighting the immediate impact of these allegations on investor confidence. The ADR price plummeted by 10.74% within just two trading sessions after the Deutsche Bank report, closing at $35.73.
Subsequently, on August 15, 2022, GSK publicly acknowledged its exposure to liabilities relating to Zantac, further deteriorating its stock price by 3% to close at $34.95. This disclosure has left many investors questioning the company's responsibility regarding its products and the potentially extensive repercussions of these legal challenges.
As Pomerantz LLP proceeds with the class action lawsuit, investors are reminded to gather necessary details when reaching out regarding participation in the lawsuit. Danielle Peyton, a representative from Pomerantz LLP, urges those interested to contact her directly, highlighting the importance of including personal details such as a mailing address and phone number for effective communication.
Founded by the late Abraham L. Pomerantz, regarded as a pioneer in the field of securities class actions, Pomerantz LLP boasts a legacy of over 85 years in advocating for investors affected by corporate misconduct. The firm has garnered a reputation for recovering lucrative damages for class members, emphasizing their commitment to justice in the realm of securities fraud.
In light of these developments, affected investors are encouraged to act swiftly to ensure their rights are protected and to obtain the requisite documentation concerning the case. The implications of the class action lawsuit could have significant impacts on GSK as well as its stakeholders, making it imperative for investors to stay informed about the situation and upcoming legal proceedings.
Potential participants can visit the Pomerantz LLP website, www.pomerantzlaw.com, for more information and to access the relevant legal documents. As the situation unfolds, stakeholders will be closely watching how the legal landscape impacts GSK and the pharmaceutical industry at large.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.